Medical Condition News

RSS

Enobia Pharma unveils findings from first HPP self-reported patient survey at ACMG 2010

Enobia Pharma Inc. unveiled findings from the first hypophosphatasia self-reported patient survey intended to evaluate the burden of illness associated with HPP at the 2010 American College of Medical Genetics Annual Clinical Genetics Meeting.

30 Mar 2010

LCT receives approval for New Zealand Phase II human trial of DIABECELL

Living Cell Technologies Limited, a global company pioneering the development of a cell implant to treat diabetes, today announced that it has received approval to advance to the next phase of its New Zealand Phase II human clinical trial with its groundbreaking DIABECELL®. The approval follows a positive assessment from the New Zealand Data Safety and Monitoring Board of the first four patients to receive its DIABACELL® implants.

30 Mar 2010

GenVec announces discontinuation of TNFerade PACT trial for pancreatic cancer

GenVec, Inc. announced today that it is discontinuing its Phase 3 clinical trial of TNFerade™ in patients with locally advanced pancreatic cancer based on results of an interim analysis. This interim analysis of overall survival, conducted after the 184th death (two-thirds of total expected events), was designed to determine whether the study should continue.

30 Mar 2010

Researchers to study health literacy among Indigenous people living with cardiovascular disease

Researchers at St. Michael's Hospital in Toronto are part of an international team of researchers recently awarded a multi-million dollar grant for their work in cardiovascular disease among Indigenous people in Canada, Australia and New Zealand. The Canadian team will receive $742,000 in funding for its part of the project from the Canadian Institutes of Health Research and International Collaborative Indigenous Health Research Partnerships.

30 Mar 2010

Cephalon receives FDA Complete Response Letter for NUVIGIL supplemental new drug application

Cephalon, Inc. today announced the company has received a Complete Response letter from the U.S. Food and Drug Administration (FDA) for its supplemental new drug application for NUVIGIL® (armodafinil) Tablets [C-IV] in the treatment of patients with excessive sleepiness associated with jet lag disorder resulting from eastbound travel.

30 Mar 2010

NexMed files IND with FDA for Phase II trial of PrevOnco for HCC

NexMed, Inc, a specialty CRO with a pipeline of products based on the NexACT® technology, today announced that the Company has filed an Investigational New Drug (IND) application with the U.S. Food & Drug Administration (FDA) for a Phase II trial of its recently acquired cancer drug candidate PrevOnco™, in combination with doxorubicin in patients with advanced, unresectable hepatocellular carcinoma (HCC). The FDA has 30 days to comment on the IND before NexMed can proceed with human testing.

29 Mar 2010

Unrestricted availability of food can trigger overconsumption and obesity

Some of the same brain mechanisms that fuel drug addiction in humans accompany the emergence of compulsive eating behaviors and the development of obesity in animals, according to research funded by the National Institute on Drug Abuse (NIDA), a component of the National Institutes of Health.

29 Mar 2010

Generex Biotechnology announces FDA Expanded Access Treatment IND Program for Generex Oral-lyn

Generex Biotechnology Corporation, the leader in drug delivery for metabolic diseases through the inner lining of the mouth, today announced that it has expanded its plans for its United States Food and Drug Administration (FDA) Expanded Access Treatment IND Program for its flagship product, Generex Oral-lyn™, to include licensed and qualified Nurse Practitioners in the United States.

29 Mar 2010

Ligand Pharmaceuticals' LGD-4033 SARM Phase I study data featured at 14th endocrinology congress

Ligand Pharmaceuticals Incorporated today announced that data from a Phase I study with its selective androgen receptor modulator (SARM) LGD-4033 was featured today in a poster presentation at the 14th International Congress of Endocrinology in Kyoto, Japan. This Phase I clinical trial was the first study in humans of LGD-4033, and evaluated the safety, tolerability and pharmacokinetic profiles of the molecule in a single escalating dose, double blind, placebo-controlled study in 48 healthy volunteers.

29 Mar 2010

Oxygen Biotherapeutics commences distributing newly formulated Dermacyte Oxygen Concentrate

Oxygen Biotherapeutics, Inc. today announced that the company has begun distribution for its newly formulated Dermacyte™ Oxygen Concentrate for the beauty and skin care market. The over-the-counter product is a scientifically designed perfluorocarbon concentrate to enhance oxygen delivery to skin.

29 Mar 2010

Enrollment complete in Gemin X Pharmaceuticals' Phase 2 clinical trial of obatoclax for SCLC

Gemin X Pharmaceuticals, a clinical stage biopharmaceutical company developing novel, targeted cancer therapeutics, today announced the completion of patient enrollment in a Phase 2 clinical trial of the Company's lead product candidate obatoclax (GX15-070) for the treatment of extensive-stage small cell lung cancer (SCLC). The trial is designed to evaluate the efficacy and safety of obatoclax, a novel pan Bcl-2 inhibitor, in combination with standard chemotherapy for the first-line treatment of patients with SCLC.

29 Mar 2010

Upgrading to policy with no limits benefits insurance agent

It can be instructive to consider not just what long term care insurance professionals recommend, but what they do -- for their own personal protection. A good example is the case of Kim Galatolo, an agent with LTC Financial Partners LLC one of the nation's most experienced long term care insurance agencies. In California, where Galatolo lives and works, the firm is known as LTC Partners & Insurance Services, LLC.

29 Mar 2010

Helmholtz Zentrum München, SIRION BIOTECH partner to develop new therapeutic approaches against lymphoid tumors

Helmholtz Zentrum München has launched a new cooperative project with SIRION BIOTECH GmbH in Martinsried to develop new therapeutic approaches against lymphoid tumors. With a two-year grant from the Federal Ministry for Economics and Technology, the two partners will seek to further develop lentiviral vector systems to better understand the disease mechanisms of this cancer form and to devise approaches for treatment.

29 Mar 2010

PROCAPS granted exclusive rights to commercialize Pro-Pharmaceuticals' DAVANAT in Colombia

Pro-Pharmaceuticals, Inc., a developer of therapeutics that target Galectin receptors to treat cancer and fibrosis, today announced that it has granted PROCAPS S.A. exclusive rights to market and sell DAVANAT® to treat cancer in Colombia, South America. Phase ll clinical trial results for late-stage colorectal cancer patients demonstrate that when DAVANAT® is co-administered with the chemotherapy drug 5-FU, survival increased by 46% over the best standard of care and reduced serious adverse events associated with chemotherapy.

29 Mar 2010

Surgery helps reduce weight from 118 kg to 62.8 kg

Weight control is one of the important topics for modern people. In addition to proper diet, regular exercise and appropriate use of medicine, obese suffers may consider weight loss surgeries for faster effects. The first successful case in NCKU Hospital reduced her weight from 118 kg to 62.8 kg one year after the surgery.

29 Mar 2010

Research explores association between BP and psychopathological symptoms

A paper published in the current issue of Psychotherapy and Psychosomatics addresses the relationship of body piercing with psychopathology. The term 'body piercing' refers to the 'insertion of jewellery and other objects into artificially made openings in body parts', while body modifications encompass BP and tattoos. Recent research has explored the association between BP and psychopathological symptoms with unclear results.

29 Mar 2010

High fructose corn syrup linked to skyrocketing rates of obesity

According to the Centers for Disease Control and Prevention, the rates of obesity in the United States have skyrocketed since the introduction of high fructose corn syrup in 1970. In that time, obesity rates have gone from 15 percent of the U.S. population to roughly one-third.

29 Mar 2010

Ethical guidelines needed for research on persons with impaired decision making

How do we handle the ethical dilemmas of research on adults who can't give their informed consent? In a recent article in the journal Bioethics, ethicist Stefan Eriksson proposes a new approach to the dilemma of including dementia patients and others with limited decision making capabilities in research.

29 Mar 2010

Naturalhealthylife.co.uk celebrates National Garlic Day

Naturalhealthylife.co.uk, the official UK site for herbal supplements made by Klosterfrau, are celebrating National Garlic Day on Monday 19th April. Klosterfrau is a leading manufacturer of herbal healthcare products.

29 Mar 2010

American obesity problem: Ongoing support to make lifestyle and behavior changes needed

An administration task force chaired by the U.S. Departments of Agriculture, Education and Health and Human Services is asking the public for recommendations to solve the American obesity problem, and a new poll by the American Psychological Association may have some answers.

29 Mar 2010

Medical Condition News

Enobia Pharma unveils findings from first HPP self-reported patient survey at ACMG 2010

LCT receives approval for New Zealand Phase II human trial of DIABECELL

GenVec announces discontinuation of TNFerade PACT trial for pancreatic cancer

Researchers to study health literacy among Indigenous people living with cardiovascular disease

Cephalon receives FDA Complete Response Letter for NUVIGIL supplemental new drug application

NexMed files IND with FDA for Phase II trial of PrevOnco for HCC

Unrestricted availability of food can trigger overconsumption and obesity

Generex Biotechnology announces FDA Expanded Access Treatment IND Program for Generex Oral-lyn

Ligand Pharmaceuticals' LGD-4033 SARM Phase I study data featured at 14th endocrinology congress

Oxygen Biotherapeutics commences distributing newly formulated Dermacyte Oxygen Concentrate

Enrollment complete in Gemin X Pharmaceuticals' Phase 2 clinical trial of obatoclax for SCLC

Upgrading to policy with no limits benefits insurance agent

Helmholtz Zentrum München, SIRION BIOTECH partner to develop new therapeutic approaches against lymphoid tumors

PROCAPS granted exclusive rights to commercialize Pro-Pharmaceuticals' DAVANAT in Colombia

Surgery helps reduce weight from 118 kg to 62.8 kg

Research explores association between BP and psychopathological symptoms

High fructose corn syrup linked to skyrocketing rates of obesity

Ethical guidelines needed for research on persons with impaired decision making

Naturalhealthylife.co.uk celebrates National Garlic Day

American obesity problem: Ongoing support to make lifestyle and behavior changes needed

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Precision in every drop: Inside Hamilton’s syringe technology

Latest News